3,5-Dimethyl-1H-pyrazole-4-carboxylic acid, 97.0%, 5g

5-(4-NITROPHENYL)-1H-TETRAZOLE, 97%, 10g

4-Bromo-2,5-dichloro-6-fluorobenzaldehyde, 250mg

5-Amino-2-chloro-4-methylpyridine, 95.0%, 10g

tert-Butyl ((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate, 98%, 250mg

2-chloro-6-(1H-imidazol-1-yl)pyridine, 95.0%, 1g

(4-(Aminomethyl)-3-fluorophenyl)boronic acid hydrochloride, 95.0%, 100mg

[2,2':6',2''-Terpyridine]-4'-carboxylic acid, 95.0%, 25g

2-Fluoro-2-(4-fluorophenyl)acetic acid, 95%, 100mg

Microliter syringe GASTIGHT® series 1700 Point type 3, 50 µl, 1705 RNR, 1 piece

8-Bromo-3-chloroisoquinoline, 95+%, 100mg

5-Bromo-2-methyl-8-quinolinamine, 97%, 500mg

3-Phenylbenzyl amine, 95.0%, 25g